PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
PROTHENA CORP PUBLIC LTD CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.48+0.13 (+1.56%)
Close on Oct 19, 2026
- Market cap
- $442.19M
- P/E (TTM)
- –
- Dividend yield
- –
PROTHENA CORP PUBLIC LTD CO revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $1.01M | $1.03M | $21.00K | $2.42M | $4.42M | $2.78M | $2.12M | $970.00K | $132.01M | $0 | $316.00K | $84.87M | 100.0% | -77.1% |
| Revenue from license and intellectual property | $0 | $50.05M | $0 | $0 | $0 | $50.00K | $0 | $0 | $0 | $50.00K | $0 | $0 | 0.0% | – |
By region
From the segment and revenue-disaggregation notes of Prothena Corp Public's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.